Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of Pulmatrix stock opened at $5.75 on Thursday. The firm has a market cap of $20.99 million, a PE ratio of -2.18 and a beta of 1.54. The business’s 50 day simple moving average is $3.89 and its 200 day simple moving average is $2.69. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $8.44.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.